Serotonin syndrome: Recognition and treatment

AACN Advanced Critical Care

Volumn 24, Issue 1, 2013, Pages 15-20

  Cooper, Brad E ^a   Sejnowski, Celeste A ^a  

^a HAMOT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONTINUING EDUCATION; HUMAN; PATHOPHYSIOLOGY; SEROTONIN SYNDROME;

EDUCATION, CONTINUING; HUMANS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 84873429007     PISSN: 15597768     EISSN: 15597776     Source Type: Journal    
DOI: 10.1097/NCI.0b013e31827eecc6     Document Type: Conference Paper

References (28)

1. Boyer E, Shannon M. The serotonin syndrome. N Engl J Med. 2005 ; 352 : 1112-1120.
2. Mills KC. Serotonin syndrome: A clinical update. Crit Care Clin. 1997 ; 13 : 763-783. (Pubitemid 27432892)
3. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999 ; 49 : 871-874 (Pubitemid 29504898)
4. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2003 ; 21 : 353-421.
5. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005; 23 : 589.
6. McAllen KJ, Rhoney DH. Drug-induced hyperthermia. In: Papadopoulos J, Cooper BE, Kane-Gill S, Mallow-Corbett S, Barletta JF, eds. Drug Induced Complications in the Critically Ill Patient: A Guide for Recognition and Treatment. Mount Prospect, IL: Society of Critical Care Medicine; 2012 : 127-143.
7. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991 ; 148 : 705-713.
8. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003 ; 96 : 635-642. (Pubitemid 37063272)
9. Radomski JW, Dursum SM, Reveley MA, et al. An exploratory approach to the serotonin syndrome: An update of clinical phenomenology and revised diagnostic criteria. Med Hypothesis. 2000 ; 55 : 218-224.
10. Lane R, Baldwin D. Selective serotonin reuptake inhibitor- induced serotonin syndrome: Review. J Clin Psychopharmacol. 1997 ; 17 : 208-221. (Pubitemid 27261777)
11. Mills KC. Serotonin syndrome. Am Fam Physician. 1995 ; 52 : 1475-1482.
12. Quinn DK, Stern TA. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry. 2009 ; 11 : 353-356.
13. Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum) : An update on clinical observations. AAPS J. 2009 ; 11 : 710-727.
14. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: A review of postmarketing data. Clin Infect Dis. 2006 ; 42 : 1578-1583.
15. Facts about serotonin syndrome. Pharmacist's Lett /Prescriber's Lett. 2009 ; 25 (10) : 251002.
16. Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007 ; 45 : 315-332. (Pubitemid 46718124)
17. Stahl SM, Felker A. Monoamine oxidase inhibitors: A modern guide to an unrequited class of antidepressants. CNS Spectr. 2008 ; 13 : 855-870.
18. Dvir Y, Smallwood P. Serotonin syndrome: A complex but easily avoidable condition. Gen Hosp Psychiatry. 2008 ; 30 : 284-287. (Pubitemid 351538958)
19. O'Donnell JM, Shelton RC. Chapter 15. Drug therapy of depression and anxiety disorders. In: Brunton LL, Blumenthal DK, Murri N, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York : McGraw-Hill; 2011. www.accessmedicine.com/ content.aspx?aID=16663059. Accessed September 1, 2012.
20. Grady MM, Stahl SM. Practical guide for prescribing MAOIs: Debunking myths and removing barriers. CNS Spectr. 2012 ; 17 : 2-10.
21. Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): A review. Headache. 2010 ; 50 : 264-272.
22. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010 ; 50 : 1089-1099.
23. Sclar DA, Robison LM, Castillo LV, et al. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. Headache. 2012 ; 52 : 198-203.
24. Cappola M, Mondola R. Synthetic cathinones: Chemistry, pharmacology and toxicology of a new class of design drugs of abuse marketed as "bath salts" or "plant food." Toxicol Lett. 2012 ; 211 : 144-149.
25. Ables AZ, Nagubilli R. Prevention, diagnosis, and management of serotonin syndrome. Am Fam Physician. 2010 ; 81 : 1139-1142.
26. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999 ; 13 : 100-109. (Pubitemid 29141280)
27. Boddy R, Ali R, Dowsett R. Use of sublingual olanzapine in serotonin syndrome. J Toxicol Clin Toxicol. 2004; 42 : 725. Abstract.
28. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: A contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012 ; 24 : 155-162